Published in Cancer Res on March 15, 1996
Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation. Proc Natl Acad Sci U S A (1997) 1.00
Molecular pathogenesis of MEN2-associated tumors. Fam Cancer (2005) 0.88
Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations. Ann Surg (2002) 0.82
RET codon 609 mutations: a contribution for better clinical managing. Clinics (Sao Paulo) (2012) 0.81
Germline Mutation of the CCK Receptor: A Novel Biomarker for Pancreas Cancer. Clin Transl Gastroenterol (2016) 0.78
Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. Oncology (2016) 0.75
Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst (2000) 16.92
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet (1997) 10.71
Degenerate oligonucleotide-primed PCR: general amplification of target DNA by a single degenerate primer. Genomics (1992) 9.06
Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature (1995) 6.16
Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab (2001) 6.12
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature (1993) 5.81
Is secondary haemorrhage after tonsillectomy in adults an infective condition? Objective measures of infection in a prospective cohort. Clin Otolaryngol (2007) 5.45
P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A (1997) 5.32
Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet (1995) 4.86
Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet (1998) 4.72
Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet (2001) 4.71
Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer (1997) 4.47
Involvement of Brca2 in DNA repair. Mol Cell (1998) 4.41
Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet (1997) 4.39
Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet (1997) 4.16
Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet (2005) 4.14
An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 3.81
Complete transformation by adenovirus 2 requires both E1A proteins. Cell (1984) 3.80
Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med (1998) 3.60
Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum Mol Genet (2001) 3.58
Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet (1996) 3.53
Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol (2001) 3.35
A clonal marker induced by mutation in mouse intestinal epithelium. Nature (1988) 3.35
Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature (1994) 3.33
PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet (1999) 3.22
Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet (1992) 3.13
Cytogenetic analysis by chromosome painting using DOP-PCR amplified flow-sorted chromosomes. Genes Chromosomes Cancer (1992) 3.03
Development of the pattern of cell renewal in the crypt-villus unit of chimaeric mouse small intestine. Development (1988) 2.97
Mutations truncating the EP300 acetylase in human cancers. Nat Genet (2000) 2.84
An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet (1993) 2.79
Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol (1999) 2.79
Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet (2001) 2.77
Risk models for familial ovarian and breast cancer. Genet Epidemiol (2000) 2.75
Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell (1999) 2.71
Pneumococcal bacteraemia in two immunocompetent adults with otitis media and bronchitis. Lancet (1990) 2.59
DNA "fingerprints" and segregation analysis of multiple markers in human pedigrees. Am J Hum Genet (1986) 2.55
Familial breast cancer. BMJ (1994) 2.54
Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet (1997) 2.53
DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet (2001) 2.50
Instability of short tandem repeats (microsatellites) in human cancers. Nat Genet (1994) 2.45
A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev (1999) 2.39
Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A (2001) 2.38
Familial gastric cancer: overview and guidelines for management. J Med Genet (1999) 2.38
Derivation of mouse intestinal crypts from single progenitor cells. Nature (1985) 2.31
Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet (2004) 2.29
Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol (2000) 2.27
Deletion of genes on chromosome 1 in endocrine neoplasia. Nature (1987) 2.27
Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol (2000) 2.23
Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A (2000) 2.23
Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res (1998) 2.20
Surgery for primary hyperparathyroidism 1962-1996: indications and outcomes. Med J Aust (1998) 2.17
Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet (2000) 2.15
Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: implications for clinical predisposition testing. JAMA (1999) 2.14
Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet (1994) 2.14
Carboxyhemoglobin, cotinine, and thiocyanate assay compared for distinguishing smokers from non-smokers. Clin Chem (1984) 2.12
PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Hum Mol Genet (1999) 2.08
Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res (1997) 2.06
Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet (2000) 2.05
Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol (2000) 2.05
Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet (1994) 2.04
Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease. Hum Mutat (1997) 2.04
The extent of linkage disequilibrium in four populations with distinct demographic histories. Am J Hum Genet (2000) 2.03
The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours. Oncogene (1989) 2.02
Cell migration pathway in the intestinal epithelium: an in situ marker system using mouse aggregation chimeras. Cell (1985) 2.02
Apolipoprotein L gene family: tissue-specific expression, splicing, promoter regions; discovery of a new gene. J Lipid Res (2001) 2.02
PTEN mutations in gliomas and glioneuronal tumors. Oncogene (1998) 2.01
Mutation of the endothelin-3 gene in the Waardenburg-Hirschsprung disease (Shah-Waardenburg syndrome). Nat Genet (1996) 2.01
Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene (1998) 1.97
Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J Med Genet (2004) 1.96
A polymorphic stop codon in BRCA2. Nat Genet (1996) 1.95
Stem-cell organization in mouse small intestine. Proc Biol Sci (1990) 1.93
PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum Mol Genet (2001) 1.87
Molecular characterisation of a common SDHB deletion in paraganglioma patients. J Med Genet (2007) 1.86
PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Res (1999) 1.85
Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis. Hum Mol Genet (2000) 1.84
Molecular identification of latent precancers in histologically normal endometrium. Cancer Res (2001) 1.84
Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II. JAMA (1995) 1.83
Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol (2001) 1.82
Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes. Am J Hum Genet (2001) 1.81
A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet (2000) 1.80
Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet (1996) 1.79
Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Res (2000) 1.78
Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol Oncol (1997) 1.73
Rapid detection of regionally clustered germ-line BRCA1 mutations by multiplex heteroduplex analysis. UKCCCR Familial Ovarian Cancer Study Group. Am J Hum Genet (1996) 1.72
Genetic mapping of DNA segments relative to the locus for the fragile-X syndrome at Xq27.3. Am J Hum Genet (1985) 1.71
Targeted mutagenesis of Smad1 reveals an essential role in chorioallantoic fusion. Dev Biol (2001) 1.71
A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol (1998) 1.70
The arrangement of nucleosomes in nucleoprotein complexes from polyoma virus and SV40. Cell (1977) 1.69